Biotech | 02 August 2022
UBC acquires Examoto
With this acquisition, UBC provides the most comprehensive REMS services and innovative risk mitigation solutions for the biopharmaceutical industry
With this acquisition, UBC provides the most comprehensive REMS services and innovative risk mitigation solutions for the biopharmaceutical industry
Advancing to IND-enabling studies with multiple drug candidates
AbTis will have access to WuXi XDC's integrated services for linker and payload manufacturing
The research here will mainly concentrate on the manufacturing process of biopharmaceuticals, especially in the area of advanced medicines, as well as the fermentation-based manufacture of ingredients for foods and food supplements
The new program includes upstream and downstream process development and large-scale GMP production.
SPLASH also houses the tools’ calibration for epMotion, Eppendorf automated liquid handling workstations.
We have grown from $10 billion to $80 billion. India is not too far from reaching the league of top-10 countries in Biotech's global ecosystem”
Bayer now present in four of the largest biotechnology hubs in the United States
Trial will assess safety and antibody responses of NVX-CoV2515 to the Omicron variant of COVID-19
The abstract is about the cohort A, stage I of the ongoing global phase ? trial that evaluating the safety and efficacy of Catumaxomab in advanced GC patients with peritoneal metastasis
OS-SiA is the industry’s first AI-enabled digital scanner that will provide real-time predictive analysis and actionable insights
Already an existing partner and supplier of ingredients to Medisca, striking this agreement with SUANFARMA involved reinforcing a well-established symbiotic relationship between two companies committed to world-class quality, service, and price
The inspection was a Pre-Approval cum cGMP inspection and it covered 15 ANDAs
Opdivo-based treatments are now approved for five indications in upper gastroesophageal cancers
68% of patients receiving Kymriah in the ELARA trial experienced a complete response, with an 86% overall response rate, along with a remarkable safety profile
RSV is the most common viral cause of respiratory tract infections in newborns, young children, older adults, or the immunocompromised
Researchers found that the drug combination led to a sustained and tenfold increase in the production of CD8 T cells and natural killer cells
Lung cancer is the leading cause of cancer death in the USA, making up almost 25% of all cancer deaths
Data from the three studies formed the basis of the company's application for approval by regulatory agencies
Glofitamab has the potential to offer a readily available, fixed-duration CD20xCD3 bispecific antibody treatment approach for people with aggressive lymphoma
Subscribe To Our Newsletter & Stay Updated
